Freenome, Abbott Laboratories' Colorectal Cancer Screening Test Approved by FDA; Freenome Earns $100 Million Milestone Payment
MT Newswires Live
Jul 27
Freenome (FRNM) and Abbott Laboratories (ABT) said Monday that the US Food and Drug Administration approved SimpleScreen CRC, a blood-based colorectal cancer screening test.
The companies said the new blood-based screening option is intended for adults 45 and older who are at average risk for the disease.
Under the terms of a commercial agreement between Freenome and Abbott, Freenome will receive a $100 million milestone payment from Abbott for the FDA approval, while Abbott will exclusively commercialize the test in the US this fall.
Shares of Freenome were up close to 10% pre-bell.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.